Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection : The HERO Study
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Background: Depressive symptoms are prevalent among people who inject drugs (PWID) and people with hepatitis C virus (HCV). We examined changes in depressive symptoms among HCV-infected PWID following direct-acting antiviral treatments to evaluate whether these changes differed by history of depressive symptoms, substance use, or HCV treatment outcome.
Methods: We conducted a secondary analysis of the HERO Study (NCT02824640), a pragmatic randomized clinical trial among PWID, to test the effectiveness of HCV care models. Depressive symptoms (primary outcome) were measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of treatment (EOT), and at follow-up 12 and 24 weeks after EOT. Sustained virologic response (SVR) was defined as undetectable HCV RNA at ≥12 weeks following EOT. Baseline drug use was defined as having a positive urine screening test for amphetamine, methamphetamine, benzodiazepine, cocaine, cannabis, opiate, or oxycodone.
Results: The sample (n = 498) was 72.3% male, 64.2% White, and on average 43.9 years old. In patients who achieved SVR (F(3432) = 4.58; P = .004) and those with drug use at baseline (F(3478) = 5.11; P < .01), PHQ-9 scores significantly declined over time, with scores lower at EOT and both follow-ups as compared with baseline. Mean PHQ-9 scores at EOT and follow-ups were significantly lower than at baseline, except for those with no depression or mild depression at baseline.
Conclusions: This study showed that HCV treatment in PWID is associated with sustained declines in depression up to 24 weeks post-treatment among those who achieve SVR and that drug use does not interfere with improvement in depressive symptoms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 10(2023), 11 vom: 07. Nov., Seite ofad498 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pericot-Valverde, Irene [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 11.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad498 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365147028 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365147028 | ||
| 003 | DE-627 | ||
| 005 | 20240211231936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad498 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM365147028 | ||
| 035 | |a (NLM)38023556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pericot-Valverde, Irene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection |b The HERO Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Background: Depressive symptoms are prevalent among people who inject drugs (PWID) and people with hepatitis C virus (HCV). We examined changes in depressive symptoms among HCV-infected PWID following direct-acting antiviral treatments to evaluate whether these changes differed by history of depressive symptoms, substance use, or HCV treatment outcome | ||
| 520 | |a Methods: We conducted a secondary analysis of the HERO Study (NCT02824640), a pragmatic randomized clinical trial among PWID, to test the effectiveness of HCV care models. Depressive symptoms (primary outcome) were measured using the Patient Health Questionnaire (PHQ-9) at baseline, end of treatment (EOT), and at follow-up 12 and 24 weeks after EOT. Sustained virologic response (SVR) was defined as undetectable HCV RNA at ≥12 weeks following EOT. Baseline drug use was defined as having a positive urine screening test for amphetamine, methamphetamine, benzodiazepine, cocaine, cannabis, opiate, or oxycodone | ||
| 520 | |a Results: The sample (n = 498) was 72.3% male, 64.2% White, and on average 43.9 years old. In patients who achieved SVR (F(3432) = 4.58; P = .004) and those with drug use at baseline (F(3478) = 5.11; P < .01), PHQ-9 scores significantly declined over time, with scores lower at EOT and both follow-ups as compared with baseline. Mean PHQ-9 scores at EOT and follow-ups were significantly lower than at baseline, except for those with no depression or mild depression at baseline | ||
| 520 | |a Conclusions: This study showed that HCV treatment in PWID is associated with sustained declines in depression up to 24 weeks post-treatment among those who achieve SVR and that drug use does not interfere with improvement in depressive symptoms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DAA medication | |
| 650 | 4 | |a HCV | |
| 650 | 4 | |a PWID | |
| 650 | 4 | |a depression | |
| 700 | 1 | |a Lopes, Snehal S |e verfasserin |4 aut | |
| 700 | 1 | |a Nahvi, Shadi |e verfasserin |4 aut | |
| 700 | 1 | |a Thrasher, James F |e verfasserin |4 aut | |
| 700 | 1 | |a Karasz, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Lynn E |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Shruti H |e verfasserin |4 aut | |
| 700 | 1 | |a Lum, Paula J |e verfasserin |4 aut | |
| 700 | 1 | |a Tsui, Judith I |e verfasserin |4 aut | |
| 700 | 1 | |a Page, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Feinberg, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Arthur Y |e verfasserin |4 aut | |
| 700 | 1 | |a Norton, Brianna L |e verfasserin |4 aut | |
| 700 | 1 | |a Arnsten, Julia H |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Artamendi, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Heo, Moonseong |e verfasserin |4 aut | |
| 700 | 1 | |a Litwin, Alain |e verfasserin |4 aut | |
| 700 | 0 | |a HERO Research Group |e verfasserin |4 aut | |
| 700 | 1 | |a Litwin, Alain H |e investigator |4 oth | |
| 700 | 1 | |a Heo, Moonseong |e investigator |4 oth | |
| 700 | 1 | |a Pericot-Valverde, Irene |e investigator |4 oth | |
| 700 | 1 | |a Walker, Hagan |e investigator |4 oth | |
| 700 | 1 | |a Coleman, And Ashley |e investigator |4 oth | |
| 700 | 1 | |a Mehta, Shruti H |e investigator |4 oth | |
| 700 | 1 | |a Borsuk, Courtney |e investigator |4 oth | |
| 700 | 1 | |a Dickerson, Brian |e investigator |4 oth | |
| 700 | 1 | |a Falade-Nwulia, Oluwaseun |e investigator |4 oth | |
| 700 | 1 | |a Fingerhood, Michael |e investigator |4 oth | |
| 700 | 1 | |a Haselhuhn, Taryn |e investigator |4 oth | |
| 700 | 1 | |a Mason, Angela |e investigator |4 oth | |
| 700 | 1 | |a Moon, Juhi |e investigator |4 oth | |
| 700 | 1 | |a Olsen, Yngvild |e investigator |4 oth | |
| 700 | 1 | |a Walters, And Vickie |e investigator |4 oth | |
| 700 | 1 | |a Kim, Arthur Y |e investigator |4 oth | |
| 700 | 1 | |a Roche, Jillian M |e investigator |4 oth | |
| 700 | 1 | |a Schmitt, William |e investigator |4 oth | |
| 700 | 1 | |a Lijewski, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Pitts, Anita |e investigator |4 oth | |
| 700 | 1 | |a Raji, Syeda |e investigator |4 oth | |
| 700 | 1 | |a Silva, Taniya |e investigator |4 oth | |
| 700 | 1 | |a Evans, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Koene, Hope |e investigator |4 oth | |
| 700 | 1 | |a Brown, Joelle |e investigator |4 oth | |
| 700 | 1 | |a Norton, Brianna |e investigator |4 oth | |
| 700 | 1 | |a Agyemang, Linda |e investigator |4 oth | |
| 700 | 1 | |a Arnsten, Julia |e investigator |4 oth | |
| 700 | 1 | |a Karasz, Alison |e investigator |4 oth | |
| 700 | 1 | |a Meissner, Paul |e investigator |4 oth | |
| 700 | 1 | |a Lora, Kiara |e investigator |4 oth | |
| 700 | 1 | |a Hidalgo, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Soloway, Irene |e investigator |4 oth | |
| 700 | 1 | |a Jefferson, Karen |e investigator |4 oth | |
| 700 | 1 | |a Wong, Joyce |e investigator |4 oth | |
| 700 | 1 | |a Kermack, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Stein, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Joseph, Gilian |e investigator |4 oth | |
| 700 | 1 | |a London, Karyn |e investigator |4 oth | |
| 700 | 1 | |a Allen, Lincoln |e investigator |4 oth | |
| 700 | 1 | |a Marte, Venecia |e investigator |4 oth | |
| 700 | 1 | |a Vera, Tatiana |e investigator |4 oth | |
| 700 | 1 | |a Alvarez, And Romy |e investigator |4 oth | |
| 700 | 1 | |a Mckee, M Diane |e investigator |4 oth | |
| 700 | 1 | |a Lum, Paula J |e investigator |4 oth | |
| 700 | 1 | |a Stein, Ellen S |e investigator |4 oth | |
| 700 | 1 | |a Luetkemeyer, Anne F |e investigator |4 oth | |
| 700 | 1 | |a Cullen, Caycee |e investigator |4 oth | |
| 700 | 1 | |a Gill, Gurjot |e investigator |4 oth | |
| 700 | 1 | |a Tierney, Hannah |e investigator |4 oth | |
| 700 | 1 | |a Shapiro, Scott |e investigator |4 oth | |
| 700 | 1 | |a Azari, Soraya |e investigator |4 oth | |
| 700 | 1 | |a Eveland, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Berrner, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Grey, Pauli |e investigator |4 oth | |
| 700 | 1 | |a Akerley, And Jordan |e investigator |4 oth | |
| 700 | 1 | |a Page, Kimberly |e investigator |4 oth | |
| 700 | 1 | |a Wagner, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Davis, Herbert |e investigator |4 oth | |
| 700 | 1 | |a Murray-Krezan, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Jacobsohn, Vanessa |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Taylor, Lynn E |e investigator |4 oth | |
| 700 | 1 | |a Tashima, Karen |e investigator |4 oth | |
| 700 | 1 | |a Sprecht-Walsh, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Aurielle |e investigator |4 oth | |
| 700 | 1 | |a Hordes, Melissa |e investigator |4 oth | |
| 700 | 1 | |a McGregor, Danielle |e investigator |4 oth | |
| 700 | 1 | |a Duryea, Patrick |e investigator |4 oth | |
| 700 | 1 | |a Weenig, And Kathryn |e investigator |4 oth | |
| 700 | 1 | |a Tsui, Judith I |e investigator |4 oth | |
| 700 | 1 | |a Blalock, Kendra L |e investigator |4 oth | |
| 700 | 1 | |a Kim, Hyang Nina |e investigator |4 oth | |
| 700 | 1 | |a Ramchandani, Meena S |e investigator |4 oth | |
| 700 | 1 | |a James, Jocelyn R |e investigator |4 oth | |
| 700 | 1 | |a Peavy, K Michelle |e investigator |4 oth | |
| 700 | 1 | |a Grekin, Paul |e investigator |4 oth | |
| 700 | 1 | |a Ninburg, And Michael |e investigator |4 oth | |
| 700 | 1 | |a Feinberg, Judith |e investigator |4 oth | |
| 700 | 1 | |a Wilkinson, Samuel |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Danielle |e investigator |4 oth | |
| 700 | 1 | |a Kelley, Lacey |e investigator |4 oth | |
| 700 | 1 | |a Calkins, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Henry, Gabrielle |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 10(2023), 11 vom: 07. Nov., Seite ofad498 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:11 |g day:07 |g month:11 |g pages:ofad498 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad498 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 11 |b 07 |c 11 |h ofad498 | ||